Author:
Imran Ghare Mohammed,Lansky Alexandra, ,
Abstract
Transcatheter aortic valve replacement is a groundbreaking treatment modality for severe, symptomatic aortic stenosis. Despite the rapid progression in indications to include intermediate-risk patients, the risk of peri-procedural stroke remains, with a higher incidence rate than previously reported. Accurate assessment of peri-procedural stroke rates requires selection of careful and meaningful trial endpoints during evaluation of neuroprotective devices. In this article, we review recommendations and stroke definitions from academic research consortiums along with device trial results.
Subject
Cardiology and Cardiovascular Medicine
Reference69 articles.
1. Transcatheter aortic valve replacement in Europe;Mylotte;J Am Coll Cardiol,2013
2. 2. Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385:2485-91.
3. Two-year outcomes after transcatheter or surgical aortic-valve replacement;Kodali;N Engl J Med,2012
4. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery;Leon;N Engl J Med,2010
5. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients;Reardon;N Engl J Med,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献